Sales and Earnings for 2000 4th Quarter and Full Year. Schering-Plough press release,
January 25, 2000.
SEC 10-K Annual Financial Filing. Contains sales figures and patent expiration dates for
the company's ten largest selling drugs, firm-level R&D figures, information on lawsuits filed
against the firm, income and cost data, stock information, financial holdings, and a complete
list of BMS's subsidiaries.
Notice of 2000 Annual Meeting and Proxy Statement. Contains exececutive compensation figures,
including salaries and stock options.
Out going CEO Richard J. Kogan's salary and stock options from the AFL-CIO's page on
executive compensation. Also, see
a more detailed breakdown of his executive
compensation and severence package from Business.com.
Political Donations and Lobbying, USA
Drugs Related to IPR Disputes
Schering-Plough's patent on Claritin is set to expire in 2002. According to SEC filings,
Schering-Plough made $2.7 billion in sales of Claritin in 1999, and $2.3 billion in 1998. In
order to prevent competition from generics when the patent expires, the company has
been lobbying hard for an extention of patent rights.
- K-Dur 20
2000 Galloping Hill Road
Kenilworth, N.J. 07033-0530
WASHINGTON, DC OFFICE
Scgering-Plough Legislative Resources, LLC
1130 Connecticut Ave., NW # 500
Washington, DC, 20036
Richard J. Kinney, Staff V.P., Public Affiars
CPT Intellectual Property and Healthcare page
CPT Companies page